Neuromodulation for Parkinson's Disease

FF
Overseen ByFelipe Fregni
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Felipe Fregni, MD, PhD, MPH
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study will compare different treatment schedules of combined transcranial direct current stimulation (tDCS) and transcranial ultrasound stimulation (TUS) in participants with Parkinson's disease. Participants will be randomly assigned to one of four groups: Standard (10 sessions delivered five times per week for two weeks), Distributed (six sessions delivered three times per week for two weeks), Short (five sessions delivered over one week), or Sham (10 sham sessions delivered five times per week for two weeks).

Are You a Good Fit for This Trial?

This trial is for people diagnosed with Parkinson's disease. Participants should not have any conditions that would make it unsafe to receive brain stimulation treatments.

Inclusion Criteria

I have moderate movement problems even when taking my medication.
I have Parkinson's disease and problems with balance or standing.
I am between 40 and 85 years old.
See 1 more

Exclusion Criteria

I have epilepsy or a condition that puts me at high risk for seizures.
My disease stage is 2 or less, or greater than 4 on the Hoehn and Yahr scale.
I do not have any conditions that prevent me from safely receiving brain stimulation treatments.
See 8 more

What Are the Treatments Tested in This Trial?

Interventions

  • tDCS combined with TUS

Trial Overview

The study tests different schedules of two non-invasive brain stimulation techniques—tDCS and TUS—either alone or together, compared to a sham (placebo) treatment. Participants are randomly assigned to one of four groups.

How Is the Trial Designed?

4

Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: Standard ProtocolExperimental Treatment1 Intervention
Group II: Short ProtocolActive Control1 Intervention
Group III: Distributed ProtocolActive Control1 Intervention
Group IV: ShamPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Felipe Fregni, MD, PhD, MPH

Lead Sponsor